{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:08:35Z","timestamp":1788790115771,"version":"build-2803163510"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Programmed death 1 (PD-1) inhibitors have transformed the treatment of advanced non-small cell lung cancer (NSCLC), but durable responses remain limited to a subset of patients. Conventional biomarkers, including PD-L1 expression and tumor mutational burden, are constrained by tissue accessibility, intratumoral heterogeneity, and limited capacity for dynamic monitoring. Circulating cytokines offer a minimally invasive alternative because they reflect systemic inflammation, antitumor immunity, and treatment-related immune activation. Evidence indicates that serum levels and on-treatment changes in TNF-\u03b1, IFN-\u03b3, IL-6, IL-8, IL-17A, IL-1\u03b2, IL-2, IL-5, and IL-10 are associated with response, survival, and immune-related adverse events during PD-1 blockade. In general, declines in IL-6, IL-8, IL-17A, and IL-10, together with transient increases in IFN-\u03b3 and TNF-\u03b1, may indicate favorable immune reinvigoration, although findings remain inconsistent across studies. This review summarizes the biological functions, mechanistic roles, and clinical relevance of circulating cytokines as dynamic biomarkers, evaluates their potential values and current limitations in predicting the efficacy of PD-1 inhibitor therapy in NSCLC.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1861545","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:13:21Z","timestamp":1788786801000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating cytokines as potential dynamic biomarkers of PD-1 blockade response and prognosis in non-small cell lung cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Bo","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Affiliated Hospital of Xuzhou Medical University","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Affiliated Hospital of Xuzhou Medical University","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Xuzhou First People's Hospital","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Affiliated Hospital of Xuzhou Medical University","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingpeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Affiliated Hospital of Xuzhou Medical University","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00444-8","article-title":"Global variations in lung cancer incidence by histological subtype in 2020: a population-based study","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpt.2023.09.004","article-title":"Impact of PD-1\/PD-L1 inhibitors on survival in stage III non-small-cell lung cancer: a systematic review","volume":"2","author":"Roussos","year":"2024","journal-title":"Cancer Pathogenesis Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1402017","article-title":"Association between immune-related adverse events and prognosis in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"14","author":"Ma","year":"2024"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022"},{"key":"B5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11626-024-00911-5","article-title":"PRRX1 upregulates PD-L1 in human mesenchymal stem cells","volume":"60","author":"Osawa","year":"2024","journal-title":"In Vitro Cell Dev Biol - Anim"},{"key":"B7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s13287-023-03594-z","article-title":"PD-L1 expression levels in mesenchymal stromal cells predict their therapeutic values for autoimmune hepatitis","volume":"14","author":"Bai","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1638942","article-title":"Gut microbiota and metabolites: emerging prospects in the treatment of non-small cell lung cancer","volume":"16","author":"Jiao","year":"2025"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101159","article-title":"Comprehensive metabolomic analysis identifies key biomarkers and modulators of immunotherapy response in NSCLC patients","volume":"77","author":"Lee","year":"2024","journal-title":"Drug Resistance Updates"},{"key":"B11","article-title":"The \u201cdouble-edged sword\u201d effect of cytokines in cancer: coexisting opportunities and challenges","volume":"16","author":"Yin","year":"2025"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002312","article-title":"Cytokine-based immunotherapy for gastric cancer: targeting inflammation for tumor control","volume":"6","author":"Marimuthu","year":"2025","journal-title":"Explor Target Antitumor Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.20944\/preprints202308.1647.v1","article-title":"Cytokine profile in lung cancer patients: anti-tumor and oncogenic cytokines","volume":"15","author":"Essogmo","year":"2023"},{"key":"B14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/immuno5030029","article-title":"Immune cell\u2013cytokine interplay in NSCLC and melanoma: A pilot longitudinal study of dynamic biomarker interactions","volume":"5","author":"Grecea-Balaj","year":"2025"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1699065","article-title":"Soluble cytokines and chemokines in NSCLC: drivers of immune evasion and angiogenesis","volume":"17","author":"Yang","year":"2026"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1607225","article-title":"The novel functions of chemokines in lung cancer progression","volume":"16","author":"Gong","year":"2025"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10919","DOI":"10.1038\/s41598-021-90397-y","article-title":"Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study","volume":"11","author":"Kauffmann-Guerrero","year":"2021","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 Inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1646","article-title":"The noncanonical NF\u03baB pathway: Regulatory mechanisms in health and disease","volume":"16","author":"Rodriguez","year":"2024","journal-title":"WIREs Mech Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.903679","article-title":"Tumor necrosis factor \u03b1: taking a personalized road in cancer therapy","volume":"13","author":"Ben-Baruch","year":"2022"},{"key":"B21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41577-022-00792-3","article-title":"Death by TNF: a road to inflammation","volume":"23","author":"van Loo","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.148643","article-title":"T cell-derived tumor necrosis factor induces cytotoxicity by activating RIPK1-dependent target cell death","volume":"6","author":"Chun","year":"2021","journal-title":"JCI Insight"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/bbb\/zbab226","article-title":"TNFR2 pathways are fully active in cancer regulatory T cells","volume":"86","author":"Okuzono","year":"2022","journal-title":"Biosci Biotechnol Biochem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112603","article-title":"Tumor necrosis factor receptor 2 (TNFR2): an emerging target in cancer therapy","volume":"14","author":"Medler","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168691","article-title":"TNF\u03b1 and immune checkpoint inhibition: friend or foe for lung cancer","volume":"22","author":"Benoot","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.03.020","article-title":"Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab","volume":"132","author":"Oyanagi","year":"2019","journal-title":"Lung Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107893","article-title":"Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation","volume":"194","author":"Belluomini","year":"2024","journal-title":"Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3390\/cimb47090746","article-title":"Serum TNF -\u03b1, IL-10 and IL-2 trajectories and outcomes in NSCLC and melanoma under anti-PD-1 therapy: longitudinal real-world evidence from a single center","volume":"47","author":"Grecea-Balaj","year":"2025"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030564","article-title":"Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy","volume":"13","author":"Mercogliano","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35416","article-title":"TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANF\u03b1 clinical study","volume":"157","author":"Virazels","year":"2025","journal-title":"Int J Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s43556-025-00381-5","article-title":"Interferon signaling pathways in health and disease","volume":"6","author":"Wen","year":"2025","journal-title":"Mol BioMed"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/biomedicines12061369","article-title":"Therapeutic efficacy of interferon-gamma and hypoxia-primed mesenchymal stromal cells and their extracellular vesicles: underlying mechanisms and potentials in clinical translation","volume":"12","author":"Tan","year":"2024"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110331","article-title":"PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes","volume":"38","author":"Nagasaki","year":"2022","journal-title":"Cell Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.869768","article-title":"PD-1 immune checkpoint blockade and PSGL-1 inhibition synergize to reinvigorate exhausted T cells","volume":"13","author":"Viramontes","year":"2022"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.17179\/excli2025-8617","article-title":"IFN-gamma in the tumor microenvironment: dual roles in cancer progression and therapy","volume":"24","author":"Cui","year":"2025","journal-title":"Excli J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/jp9.0000000000000113","article-title":"Double-edged roles of IFN\u03b3 in tumor elimination and immune escape","volume":"6","author":"Chen","year":"2023"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1038\/s41467-022-32754-7","article-title":"Selective suppression of melanoma lacking IFN-\u03b3 pathway by JAK inhibition depends on T cells and host TNF signaling","volume":"13","author":"Shen","year":"2022","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12943-025-02294-x","article-title":"Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors","volume":"24","author":"Wawrzyniak","year":"2025","journal-title":"Mol Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14251","article-title":"Significance of quantitative interferon-gamma levels in non-small-cell lung cancer patients' Response to immune checkpoint inhibitors","volume":"40","author":"Kanai","year":"2020","journal-title":"Anticancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918768238","article-title":"Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice","volume":"10","author":"Boutsikou","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.923531","article-title":"Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1452581","article-title":"Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab","volume":"7","author":"Costantini","year":"2018","journal-title":"Oncoimmunology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"113683","DOI":"10.1016\/j.biopha.2022.113683","article-title":"Role of interferon-gamma (IFN-\u03b3) and IFN-\u03b3 receptor 1\/2 (IFN\u03b3R1\/2) in regulation of immunity, infection, and cancer development: IFN-\u03b3-dependent or independent pathway","volume":"155","author":"Ding","year":"2022","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190333","article-title":"Dysregulation in IFN-\u03b3 signaling and response: the barricade to tumor immunotherapy","volume":"14","author":"Han","year":"2023"},{"key":"B47","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.1038\/s41467-024-51496-2","article-title":"Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade","volume":"15","author":"Holzgruber","year":"2024","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.20517\/jtgg.2025.90","article-title":"Persistent IFN-\u03b3 signaling in acquired resistance to PD-(L)1 blockade in NSCLC","volume":"9","author":"Karri","year":"2025"},{"key":"B49","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1042\/ebc20230001","article-title":"The role of IFN-\u03b3-signalling in response to immune checkpoint blockade therapy","volume":"67","author":"Wong","year":"2023","journal-title":"Essays Biochem"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-1127","article-title":"Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer","volume":"79","author":"Anagnostou","year":"2019","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/jitc-2022-sitc2022.0522","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.724722","article-title":"Patterns of failure in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"11","author":"Chai","year":"2021","journal-title":"Front Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1255533","article-title":"Interleukin 6: at the interface of human health and disease","volume":"14","author":"Grebenciucova","year":"2023"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.75876","article-title":"The role of IL-6 in fibrotic diseases: molecular and cellular mechanisms","volume":"18","author":"Li","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4110\/in.2025.25.e22","article-title":"The diverse function of IL-6 in biological processes and the advancement of cancer","volume":"25","author":"Zhou","year":"2025","journal-title":"Immune Netw"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/cells11223698","article-title":"The role of IL-6 in cancer cell invasiveness and metastasis-overview and therapeutic opportunities","volume":"11","author":"Ra\u0161kov\u00e1","year":"2022","journal-title":"Cells"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s12672-025-03644-3","article-title":"Role of interleukin-6 in resistance to tumor therapy","volume":"16","author":"Liang","year":"2025","journal-title":"Discov Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246228","article-title":"Multicellular effects of STAT3 in non-small cell lung cancer: mechanistic insights and therapeutic opportunities","volume":"13","author":"Parakh","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41419-021-03773-x","article-title":"STAT3\/miR-135b\/NF-\u03baB axis confers aggressiveness and unfavorable prognosis in non-small-cell lung cancer","volume":"12","author":"Zhao","year":"2021","journal-title":"Cell Death Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020386","article-title":"Combining STAT3-targeting agents with immune checkpoint inhibitors in NSCLC","volume":"15","author":"Papavassiliou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2023.10.035","article-title":"SIRP-alpha-IL-6 axis induces immunosuppressive macrophages in non-small-cell lung cancer","volume":"682","author":"Wang","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.7150\/thno.60040","article-title":"Converged Rab37\/IL-6 trafficking and STAT3\/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment","volume":"11","author":"Kuo","year":"2021","journal-title":"Theranostics"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1486329","article-title":"Analysis of tumor-infiltrating exhausted T cells highlights IL-6 and PD1 blockade as a combined immunotherapy strategy for non-small cell lung cancer","volume":"16","author":"Zhang","year":"2025"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.5114\/kitp.2023.134177","article-title":"A systematic review and meta-analysis to evaluate blood levels of interleukin-6 in lung cancer patients","volume":"20","author":"Jasemi","year":"2023","journal-title":"Kardiochir Torakochirurgia Pol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41698-025-01140-z","article-title":"Mechanistic insights into IL-6-mediated NK cell dysfunction in NSCLC via the IRE1\u03b1-XBP1s-STAT3-UBE2S axis","volume":"9","author":"Wang","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000678","article-title":"Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC","volume":"8","author":"Keegan","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14248","article-title":"Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy","volume":"13","author":"Shi","year":"2022","journal-title":"Thorac Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115267","article-title":"The role of IL-8 in cancer development and its impact on immunotherapy resistance","volume":"218","author":"Meier","year":"2025","journal-title":"Eur J Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00888-z","article-title":"Role of chemokines in the crosstalk between tumor and tumor-associated macrophages","volume":"23","author":"Qin","year":"2023","journal-title":"Clin Exp Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103209","article-title":"Lactate-induced activation of tumor-associated fibroblasts and IL-8-mediated macrophage recruitment promote lung cancer progression","volume":"74","author":"Gu","year":"2024","journal-title":"Redox Biol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27010137","article-title":"Roles of the CXCL8-CXCR1\/2 axis in the tumor microenvironment and immunotherapy","volume":"27","author":"Han","year":"2021","journal-title":"Molecules"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202201982rrr","article-title":"CXCL8 induces M2 macrophage polarization and inhibits CD8(+) T cell infiltration to generate an immunosuppressive microenvironment in colorectal cancer","volume":"37","author":"Shao","year":"2023","journal-title":"FASEB J"},{"key":"B73","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41419-025-07385-7","article-title":"Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies","volume":"16","author":"Luo","year":"2025","journal-title":"Cell Death Dis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2026.103135","article-title":"Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors","volume":"146","author":"Scaglione","year":"2026","journal-title":"Cancer Treat Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-0902","article-title":"High circulating IL-6\/IL-8 is associated with intratumoral myeloid contexture and poor outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade","volume":"31","author":"Carril-Ajuria","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/s41419-022-05495-0","article-title":"TRAIL receptors promote constitutive and inducible IL-8 secretion in non-small cell lung carcinoma","volume":"13","author":"Favaro","year":"2022","journal-title":"Cell Death Dis"},{"key":"B77","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.cllc.2019.08.006","article-title":"Blood predictive biomarkers for patients with non-small-cell lung cancer associated with clinical response to nivolumab","volume":"21","author":"Agull\u00f3-Ortu\u00f1o","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1176574","article-title":"Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis","volume":"13","author":"Zou","year":"2023"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1430301","article-title":"Prognostic role of serum cytokines level in non-small cell lung cancer patients with anti-PD-1 and chemotherapy combined treatment","volume":"15","author":"Liu","year":"2024"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012096","article-title":"Basic rules to respond to PD-1 blockade cancer immunotherapy","volume":"13","author":"Ribas","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01743-4","article-title":"Biomarkers of response to PD-1 pathway blockade","volume":"126","author":"Li","year":"2022","journal-title":"Br J Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.975981","article-title":"Neutrophils: musketeers against immunotherapy","volume":"12","author":"Zahid","year":"2022"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1094823","article-title":"The role of Th-17 cells and IL-17 in the metastatic spread of breast cancer: as a means of prognosis and therapeutic target","volume":"14","author":"Shibabaw","year":"2023"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190456","article-title":"Targeting the interleukin-17 immune axis for cancer immunotherapy","volume":"217","author":"Vitiello","year":"2020","journal-title":"J Exp Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520925948","article-title":"Th17 cell frequency and IL-17A production in peripheral blood of patients with non-small-cell lung cancer","volume":"48","author":"Chen","year":"2020","journal-title":"J Int Med Res"},{"key":"B87","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1186\/s12967-023-04365-3","article-title":"IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer","volume":"21","author":"Liao","year":"2023","journal-title":"J Transl Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2022.1610384","article-title":"Distribution and clinical significance of IL-17A in tumor-infiltrating lymphocytes of non-small cell lung cancer patients","volume":"28","author":"Xu","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2923998","article-title":"Correlation between the Treg\/Thl7 index and the efficacy of PD-1 monoclonal antibody in patients with advanced non-small-cell lung cancer complicated with chronic obstructive pulmonary disease","volume":"2022","author":"Wang","year":"2022","journal-title":"Comput Math Methods Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11618","article-title":"Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer","volume":"20","author":"Wang","year":"2020","journal-title":"Oncol Lett"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001895","article-title":"Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188758","article-title":"Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer","volume":"1877","author":"Li","year":"2022","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-023-01467-0","article-title":"Interleukin (IL)-17A in triple-negative breast cancer: a potent prognostic factor associated with intratumoral neutrophil infiltration","volume":"30","author":"Khalid","year":"2023","journal-title":"Breast Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.09.925","article-title":"Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade","volume":"12","author":"Akbay","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02795-2","article-title":"Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy","volume":"70","author":"Li","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B96","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00262-023-03620-2","article-title":"Predictive value of peripheral blood biomarkers in patients with non-small-cell lung cancer responding to anti-PD-1-based treatment","volume":"73","author":"Su","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156334","article-title":"Immune microenvironment of cervical cancer and the role of IL-2 in tumor promotion","volume":"170","author":"Trujillo-Cirilo","year":"2023","journal-title":"Cytokine"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-20-0431","article-title":"IL1\u03b2 promotes immune suppression in the tumor microenvironment independent of the inflammasome and gasdermin D","volume":"9","author":"Kiss","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12094-020-02392-w","article-title":"High expression level of interleukin-1\u03b2 is correlated with poor prognosis and PD-1 expression in patients with lung adenocarcinoma","volume":"23","author":"Ding","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5526885","article-title":"Serum IL-5 and IFN-\u03b3 are novel predictive biomarkers for anti-PD-1 treatment in NSCLC and GC patients","volume":"2021","author":"Zhao","year":"2021","journal-title":"Dis Markers"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12901","article-title":"Intralesional interleukin-2: a novel option to maximize response to systemic immune checkpoint therapy in loco-regional metastatic melanoma","volume":"32","author":"Langan","year":"2019","journal-title":"Dermatol Ther"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-22-0290","article-title":"Targeting the IL1\u03b2 pathway for cancer immunotherapy remodels the tumor microenvironment and enhances antitumor immune responses","volume":"11","author":"Diwanji","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-1610","article-title":"Blocking IL1 beta promotes tumor regression and remodeling of the myeloid compartment in a renal cell carcinoma model: multidimensional analyses","volume":"27","author":"Aggen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1192861","article-title":"Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1\u03b2","volume":"14","author":"Hirayama","year":"2023","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-sitc2022.1236","article-title":"Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity","volume":"132","author":"Ren","year":"2022","journal-title":"J Clin Invest"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-23-1263","article-title":"CD8-targeted IL2 unleashes tumor-specific immunity in human cancer tissue by reviving the dysfunctional T-cell pool","volume":"14","author":"Kaptein","year":"2024","journal-title":"Cancer Discov"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxac105","article-title":"IL-2-based approaches to Treg enhancement","volume":"211","author":"Harris","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.947341","article-title":"Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: a randomized controlled trial","volume":"13","author":"Wang","year":"2022"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23095066","article-title":"Eosinophils and lung cancer: from bench to bedside","volume":"23","author":"Sibille","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.764596","article-title":"The immune landscape of human primary lung tumors is Th2 skewed","volume":"12","author":"Frafjord","year":"2021"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-3016","article-title":"IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells","volume":"75","author":"Sun","year":"2015","journal-title":"Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1861545\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:13:23Z","timestamp":1788786803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1861545\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":111,"alternative-id":["10.3389\/fimmu.2026.1861545"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1861545","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1861545"}}